Psychopharmacology of lycanthropy.
OBJECTIVE
To develop pharmacotherapies for the orphan disease lycanthropy through the pursuit of the etiologic hypothesis of a genetically determined hypersecretion of endogenous lycanthropogens.


METHODS
Quadruple-blind, Rubik's Cube matrix analysis.


METHODS
Community practice and malpractice.


METHODS
Subjects selected from inbred Ruficolla populations in Mississippi, Georgia, North Carolina and Minnesota. All who entered the study finished it.


METHODS
Chemical screening of blood samples over a hypothesized secretory cycle of lycanthropogen peaking on the day of maximum lunar illumination. Administration of synthetic lycanthropogens for behavioural testing. Experimental lycosomatization through the illumination method of Kirschbaum.


METHODS
None were post hoc, but some are still in hock.


RESULTS
Two putative lycanthropogens were isolated from the blood samples. Structural elucidation and synthesis permitted animal and clinical trials; in each of these, behavioural dysfunction was observed. Antilycanthropogen strategies included application of the principle of caged compounds and generation of a therapeutic immunoglobulin. The effects of a newly developed antihirsutic agent seemed promising. An interaction of the lycanthropogen-secretion system and ethanol was noted, which may explain behavioural aspects of alcoholism.


CONCLUSIONS
The incidence of lycomania in North America is underestimated. Soon-to-be-available pharmacotherapies should promote its early detection and treatment. Full control may depend upon advances in gene therapy.
Davis
W M
WM
Orphan Drug Research Institute, Jefferson, Miss.
Wellwuff
H G
HG
Garew
L
L
Kydd
O U
OU
D003702:Delusions; D006801:Humans; D014925:Wit and Humor as Topic